NCT00002245View on ClinicalTrials.gov

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 1999

Conditions
HIV Infections
Interventions
DRUG

Abacavir sulfate

DRUG

Amprenavir

DRUG

Lamivudine

Trial Locations (1)

90033

LAC / USC Med Ctr / Infectious Diseases, Los Angeles

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY